PREDICTIVE BIOLOGY

Biotech · Private

Cerebellar organoid platform for neurotoxicant screening and disease modeling

Claim this profile

Follows are private to you and power your alerts

Updated

Sector
Biotech
Total capital
$5.8M
Federal grants
$5.1M
12 awards · 2015–2020
Rank in peer group#8 of 20
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
$654K
3 awards · Health and Human S, Environmental Prot
Rank in Biotech#213 of 4373
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

201520162017201820192020FEDERAL ↑EQUITY ↓Cumulative $5.8M$497K$491K$494K$474K$1.5M$618K
201520162017201820192020FEDERAL ↑EQUITY ↓Cumulative $5.8M$497K$494K$1.5M$618K

Latest events

  • Federal grantHealth and Human S · Phase I · Genetically diverse mouse cerebellar organoids for in vitro neurotoxicology$252K
  • Federal contractHealth and Human S · Neurotox Population Assays Phase I And Iia Studies$274K
  • Federal grantHealth and Human S · Phase II · Discovering Novel Drug Targets for CNS Edema by In Vitro Genetics$618K
  • Federal grantHealth and Human S · Phase II · Discovering Novel Drug Targets for CNS Edema by In Vitro Genetics$1.5M
  • Federal grantHealth and Human S · Phase I · Single Cell Aneugen Assay in Neural Progenitor Cells$225K
  • Federal grantHealth and Human S · Phase I · Novel Single Cell Assay to Identify Genes Underlying Developmental Neurotoxicity$225K
  • Federal grantHealth and Human S · Phase I · Discovering Novel Drug Targets for CNS Edema by In Vitro Genetics$225K
Show 7 earlier federal awards
  • Federal grantHealth and Human S · Phase I · Novel Mechanisms and Targets for Major Depressive Disorder in Astrocytes$474K
  • Federal grantHealth and Human S · Phase II · A Diversity Outbred ES Cell Panel for In Vitro Genetics of Toxicology$25K
  • Federal grantHealth and Human S · Phase II · Genetics of Drug Induced Cardiotoxicity$494K
  • Federal contractHealth and Human S · Igf::ot::igf$380K
  • Federal grantHealth and Human S · Phase II · A Diversity Outbred ES Cell Panel for In Vitro Genetics of Toxicology$491K
  • Federal grantHealth and Human S · Phase II · A Diversity Outbred ES Cell Panel for In Vitro Genetics of Toxicology$128K
  • Federal grantHealth and Human S · Phase II · Genetics of Drug Induced Cardiotoxicity$497K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

1 record has no date or no amount, so it isn’t placed on the timeline.

Standing among 20 peers

Line = median

Biotech · Material

  • Federal grants#8 · top 40%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • GALEN BIOTECHNOLOGIES, LLCSimilar federal contract value in Biotech · $727K in contracts
  • KromaTiD, Inc.Similar federal contract value in Biotech · $726K in contracts
  • APHIOS CORPORATIONSimilar federal contract value in Biotech · $723K in contracts
  • Perfinity Biosciences, Inc.Similar federal contract value in Biotech · $649K in contracts
  • iXpressGenes, Inc.Similar federal contract value in Biotech · $614K in contracts
  • NEUCYTE INCSimilar federal contract value in Biotech · $602K in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .